

DURECT CORP  
Form 8-K  
September 02, 2003

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## **Form 8-K**

### **Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**September 2, 2003**

Date of Report

(Date of earliest event reported)

## **DURECT CORPORATION**

(Exact name of Registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**000-31615**  
(Commission File Number)

**94-3297098**  
(I.R.S. Employer  
Identification No.)

**10240 Bubb Road**  
**Cupertino, CA 95014**  
(Address of principal executive offices) (Zip code)

**(408) 777-1417**  
(Registrant's telephone number, including area code)

Edgar Filing: DURECT CORP - Form 8-K

(Former name or former address, if changed since last report)

**Item 9. Regulation FD Disclosure.**

On September 2, 2003, DURECT Corporation, a Delaware corporation ( "DURECT" ) issued a press release announcing completion of the validation of the terminal sterilization manufacturing process for its CHRONOGESIC (sufentanil) Pain Therapy product.

A copy of DURECT 's press release announcing the validation is attached as Exhibit 99.1 hereto and incorporated by reference herein.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**DURECT Corporation**

Date: September 2, 2003

By:

/s/ JAMES E. BROWN

---

James E. Brown

President and Chief Executive Officer

**DURECT CORPORATION**

**INDEX TO EXHIBITS**

Exhibit Number

Description

99.1

Press Release of DURECT Corporation dated September 2, 2003.